Custopharm Inc., a U.S. producer of generic injectable devices, has acquired two Paragraph IV abbreviated new drug application products from Perrigo Co. PLC.
With the acquisition, Custopharm gains full control of an acetaminophen injection and a testosterone undecanoate injection. The former is used to reduce and alleviate pain in clinical settings, while the latter is used for testosterone replacement therapy in adult males.
The company plans to market the two products under its new commercial business arm, Leucadia Pharmaceuticals. Through this arm, Custopharm hopes to expand its product portfolio and collaborate with pharmaceutical and biotechnology companies.
"Both of these products are a tremendous fit with Custopharm's already diverse offering of specialized and high barrier generic pharmaceutical products," Custopharm CEO Dr. William Larkins said in a statement. "Our team is excited to acquire these products and begin preparations to bring lower-cost alternatives to these product categories."
In the last decade, Custopharm has developed more than 30 pharmaceutical products. In the past two years, the company has partnered with Water Street Healthcare Partners to double its laboratory capacity and the staff size of two of its research teams.